Literature DB >> 8494936

CAPD therapy for patients over 80 years of age.

N Gorban-Brennan1, A S Kliger, F O Finkelstein.   

Abstract

OBJECTIVE: The purpose of the study is to review our experience with patients over 80 years of age with end-stage renal disease (ESRD) treated with continuous ambulatory peritoneal dialysis (CAPD).
DESIGN: The records of all patients over 80 years of age treated in our unit with CAPD since 1979 were reviewed.
SETTING: Out-patient CAPD facility. PATIENTS: Eighteen patients over 80 years of age were identified and studied. MAIN OUTCOME MEASURES: The duration of CAPD therapy, duration of CAPD training, mortality rate, hospitalization rate, peritonitis rate, and family assessment were reviewed and analyzed.
RESULTS: The mean +/- SD duration of therapy was 20 +/- 17 months. Nine patients expired, 3 transferred to hemodialysis, 1 recovered renal function, and 5 remained on CAPD therapy. Peritonitis rates were 1.7 episodes/patient year. Of the organisms causing peritonitis, 56% were gram-positive bacteria. The average hospitalization rate was 13.9 days/patient year. The most frequent causes of hospitalization were peritonitis and cardiovascular disease.
CONCLUSION: CAPD therapy is a reasonable therapeutic option for patients with end-stage renal disease over 80 years of age.

Entities:  

Mesh:

Year:  1993        PMID: 8494936

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  2 in total

Review 1.  Uremic encephalopathy in patients undergoing assisted peritoneal dialysis: a case series and literature review.

Authors:  Akane Yanai; Kiyotaka Uchiyama; Yoshitaka Ishibashi
Journal:  CEN Case Rep       Date:  2019-06-08

2.  Chronic peritoneal dialysis in the tenth decade of life.

Authors:  Sham Sunder; Hulya Taskapan; Jaime Jojoa; Murali Krishnan; Mukesh Khandelwal; Sharron Izatt; Maggie Chu; Padmanabhan Subramanian; Hithaishi Chinthalapalli; Thierry Lobbedez; Saribjit Vanita Jassal; Joanne M Bargman; Dimitros G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.